TrialEBioMedicine2024

Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls.

Keren Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.